Literature DB >> 23887308

Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.

Natalie Banet1, Cheryl DeScipio2, Kathleen M Murphy3, Katie Beierl1, Emily Adams1, Russell Vang2, Brigitte M Ronnett2.   

Abstract

Immunohistochemical analysis of cyclin-dependent kinase inhibitor 1C (CDKN1C, p57, Kip2) expression and molecular genotyping accurately classify hydatidiform moles into complete and partial types and distinguish these from non-molar specimens. Characteristics of a prospective series of all potentially molar specimens encountered in a large gynecologic pathology practice are summarized. Initially, all specimens were subjected to both analyses; this was later modified to triage cases for genotyping based on p57 results: p57-negative cases diagnosed as complete hydatidiform moles without genotyping; all p57-positive cases genotyped. Of the 678 cases, 645 were definitively classified as complete hydatidiform mole (201), partial hydatidiform mole (158), non-molar (272), and androgenetic/biparental mosaic (14); 33 were unsatisfactory, complex, or problematic. Of the 201 complete hydatidiform moles, 104 were p57-negative androgenetic and an additional 95 were p57-negative (no genotyping), 1 was p57-positive (retained maternal chromosome 11) androgenetic, and 1 was p57-non-reactive androgenetic; 90 (85%) of the 106 genotyped complete hydatidiform moles were monospermic and 16 were dispermic. Of the 158 partial hydatidiform moles, 155 were diandric triploid, with 154 p57-positive, 1 p57-negative (loss of maternal chromosome 11), and 1 p57-non-reactive; 3 were triandric tetraploid, with 2 p57-positive and 1 p57-negative (loss of maternal chromosome 11). Of 155 diandric triploid partial hydatidiform moles, 153 (99%) were dispermic and 2 were monospermic. Of the 272 non-molar specimens, 259 were p57-positive biparental diploid, 5 were p57-positive digynic triploid, 2 were p57-negative biparental diploid (no morphological features of biparental hydatidiform mole), and 6 were p57-non-reactive biparental diploid. Of the 14 androgenetic/biparental mosaics with discordant p57 expression, 6 were uniformly mosaic and 8 had a p57-negative androgenetic molar component. p57 expression is highly correlated with genotyping, serves as a reliable marker for diagnosis of complete hydatidiform moles, and identifies androgenetic cell lines in mosaic conceptions. Cases with aberrant and discordant p57 expression can be correctly classified by genotyping.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887308     DOI: 10.1038/modpathol.2013.143

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Identification of a hydatidiform mole in twin pregnancy following assisted reproduction.

Authors:  Yan Liu; Xingzheng Zheng; Yuxiang Wang; Yan Li; Congrong Liu
Journal:  J Assist Reprod Genet       Date:  2019-12-12       Impact factor: 3.412

2.  Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease.

Authors:  Xing-Zheng Zheng; Xu-Ying Qin; Su-Wen Chen; Peng Wang; Yang Zhan; Ping-Ping Zhong; Natalia Buza; Yu-Lan Jin; Bing-Quan Wu; Pei Hui
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

3.  Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles.

Authors:  Ngoc Minh Phuong Nguyen; Zhao-Jia Ge; Ramesh Reddy; Somayyeh Fahiminiya; Philippe Sauthier; Rashmi Bagga; Feride Iffet Sahin; Sangeetha Mahadevan; Matthew Osmond; Magali Breguet; Kurosh Rahimi; Louise Lapensee; Karine Hovanes; Radhika Srinivasan; Ignatia B Van den Veyver; Trilochan Sahoo; Asangla Ao; Jacek Majewski; Teruko Taketo; Rima Slim
Journal:  Am J Hum Genet       Date:  2018-11-01       Impact factor: 11.025

4.  Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes.

Authors:  Yassemine Khawajkie; Nawel Mechtouf; Ngoc Minh Phuong Nguyen; Kurosh Rahimi; Magali Breguet; Jocelyne Arseneau; Brigitte M Ronnett; Lori Hoffner; Felicia Lazure; Marjolaine Arnaud; Fabrice Peers; Liane Tan; Basam Abu Rafea; Monica Aguinaga; Neil S Horowitz; Asangla Ao; Seang Lin Tan; Richard Brown; William Buckett; Urvashi Surti; Karine Hovanes; Trilochan Sahoo; Philippe Sauthier; Rima Slim
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

Review 5.  Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.

Authors:  Natalia Buza; Pei Hui
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

6.  Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles.

Authors:  K B Kubelka-Sabit; I Prodanova; D Jasar; G Bozinovski; V Filipovski; S Drakulevski; D Plaseska-Karanfilska
Journal:  Balkan J Med Genet       Date:  2017-06-30       Impact factor: 0.519

7.  Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases.

Authors:  Deyin Xing; Emily Adams; Jialing Huang; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

8.  Loss of p57 Expression in Conceptions Other Than Complete Hydatidiform Mole: A Case Series With Emphasis on the Etiology, Genetics, and Clinical Significance.

Authors:  Deyin Xing; Karin Miller; Katie Beierl; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2022-01-01       Impact factor: 6.298

Review 9.  Genetics and Epigenetics of Recurrent Hydatidiform Moles: Basic Science and Genetic Counselling.

Authors:  Ngoc Minh Phuong Nguyen; Rima Slim
Journal:  Curr Obstet Gynecol Rep       Date:  2014-01-21

10.  Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3,7,8 and unipaternal disomy of chromosome 11.

Authors:  Neil J Sebire; Philippa C May; Baljeet Kaur; Michael J Seckl; Rosemary A Fisher
Journal:  Diagn Pathol       Date:  2016-02-04       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.